Physician profile
Christopher P Robben
NPI 1669458337
$2,864.46
in general payments reported to CMS, 2019-2025
32 companies · $995 in 2025
The $995 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $300 · 2021: $129 · 2022: $121 · 2023: $170 · 2024: $420 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,585.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $510.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $383.48 | 2019-2025 | |
| Amgen INC. | $213.27 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $186.94 | 2019-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $146.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $139.38 | 2019-2020 | |
| Dexcom, INC. | $95.68 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $92.60 | 2024-2025 | Freestyle Libre 3 |
| Viiv Healthcare Company | $89.94 | 2024-2025 | Apretude |
| Abbvie INC. | $87.00 | 2025 | |
| Dynavax Technologies Corporation | $80.32 | 2021-2022 | |
| Glaxosmithkline, LLC. | $77.09 | 2020-2025 | Arexvy, Shingrix |
| Inspire Medical Systems, INC. | $75.98 | 2024-2025 | Inspire |
| Madrigal Pharmaceuticals | $70.43 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.02 | 2019-2025 | Xifaxan |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $63.09 | 2020-2024 | |
| Astellas Pharma US INC | $57.37 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $53.71 | 2019 | |
| Sanofi-Aventis U.S. LLC | $48.84 | 2019-2020 | |
| Amarin Pharma, INC. | $45.74 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.01 | 2024-2025 | |
| Vivus LLC | $35.95 | 2019 | |
| Scilex Pharmaceuticals INC. | $33.34 | 2019-2020 | |
| Ibsa Pharma INC. | $26.75 | 2019 | |
| Phathom Pharmaceuticals, INC. | $25.37 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $19.63 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.50 | 2019 | |
| Merck Sharp & Dohme LLC | $17.16 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Evoke Pharma, INC. | $17.05 | 2024 | |
| Gilead Sciences, INC. | $16.35 | 2020 | |
| Currax Pharmaceuticals LLC | $13.78 | 2020 | |
| Pulmonx Corporation | $13.34 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Robben listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.